Last quarter (Q3 2023), Longboard Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Longboard Pharmaceuticals's net income was $-12.82M. See Longboard Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20
Total Revenue	-	-	-	$ 0.00
Cost of Revenue	-	-	-	-
Gross Profit	-	-	-	-
Operating Expense	$ 29.46M	$ 44.80M	$ 27.89M	$ 14.40M
Operating Income	$ -52.89M	$ -44.80M	$ -27.89M	$ -14.40M
Net Non Operating Interest Income Expense	$ 2.23M	$ 837.00K	$ 64.00K	$ 0.00
Other Income Expense	$ -734.00K	$ 528.00K	$ 164.00K	-
Pretax Income	$ -49.94M	$ -44.44M	$ -27.99M	$ -14.40M
Tax Provision	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-
Net Income Common Stockholders	$ -50.11M	$ -44.44M	$ -27.99M	$ -14.40M
Basic EPS	$ -2.97	$ -2.56	$ -1.93	$ -0.85
Diluted EPS	$ -2.41	$ -2.56	$ -1.93	$ -0.85
Basic Average Shares	$ 84.15M	$ 17.15M	$ 14.41M	$ 16.92M
Diluted Average Shares	$ 84.15M	$ 17.15M	$ 14.41M	$ 16.92M
Dividend Per Share	-	-	-	-
Total Operating Income As Reported	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-
Rent Expense Supplemental	-	-	-	-
Total Expenses	$ 29.46M	$ 44.80M	$ 27.89M	$ 14.40M
Net Income From Continuing And Discontinued Operation	$ -50.52M	$ -43.95M	$ -27.99M	$ -14.40M
Normalized Income	-	-	-	$ -14.40M
Interest Expense	-	-	-	-
EBIT	$ -50.85M	$ -44.44M	$ -28.05M	$ -14.40M
EBITDA	$ -51.58M	$ -44.33M	$ -27.89M	$ -14.40M

Currency in USD

Longboard Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing